Fludarabine and Cytarabine as a Sequential Infusion Regimen for Treatment of Adults with Recurrent, Refractory or Poor Prognosis Acute Leukemia

• Published in: Leukemia & lymphoma Vol. 41; no. 3-4; pp. 321 - 331
• Main Authors: Vidarsson, Brynjar, Abonour, Rafat, Williams, Eliot C., Woodson, Robert D., Turman, Nancy J., Kim, Kyungmann, Mosher, Deane F., Wiersma, Susan R., Longo, Walter L.
• Format: Journal Article
• Language: English
• Published: United States Informa UK Ltd 2001; Taylor & Francis
• Subjects: Acute Disease; acute leukemia; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - toxicity; Cohort Studies; cytarabine; Cytarabine - administration & dosage; Cytarabine - toxicity; Cytogenetic Analysis; Disease-Free Survival; Drug Administration Schedule; Female; fludarabine; Hematologic Diseases - etiology; Humans; Infection - etiology; Infusion Pumps; Leukemia - complications; Leukemia - drug therapy; Leukemia - genetics; Lung Diseases - etiology; Male; Middle Aged; Nervous System Diseases - etiology; Prognosis; Recurrence; refractory; relapsed leukemia; Retrospective Studies; Survival Rate; Treatment Outcome; Vidarabine - administration & dosage; Vidarabine - analogs & derivatives; Vidarabine - toxicity

We did a retrospective analysis on the safety and efficacy of sequential infusion fludarabine and cytosine arabinoside (ara-C) in treating refractory, recurrent or poor prognosis acute leukemia in adult patients. Forty-five adult patients with acute myelogenous leukemia (AML) or acute lymphoblastic...